168 150

Cited 32 times in

Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.

Authors
 Kihyun Kim  ;  Jae Hoon Lee  ;  Jin Seok Kim  ;  Chang Ki Min  ;  Sung Soo Yoon  ;  Kazuyuki Shimizu  ;  Takaaki Chou  ;  Hiroshi Kosugi  ;  Kenshi Suzuki  ;  Wenming Chen  ;  Jian Hou  ;  Jin Lu  ;  Xiao-Jun Huang  ;  Shang-Yi Huang  ;  Wee Joo Chng  ;  Daryl Tan  ;  Gerrard Teoh  ;  Chor Sang Chim  ;  Weerasak Nawarawong  ;  Noppadol Siritanaratkul  ;  Brian G. Durie 
Citation
 AMERICAN JOURNAL OF HEMATOLOGY, Vol.89(7) : 751-756, 2014 
Journal Title
 AMERICAN JOURNAL OF HEMATOLOGY 
ISSN
 0361-8609 
Issue Date
2014
MeSH
Adult ; Aged ; Aged, 80 and over ; Asia/epidemiology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Multiple Myeloma/epidemiology* ; Multiple Myeloma/ethnology ; Multiple Myeloma/pathology ; Multiple Myeloma/therapy ; Prognosis ; Retrospective Studies ; Survival Analysis ; Young Adult
Abstract
The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P < 0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first-line treatment
Files in This Item:
T201405629.pdf Download
DOI
10.1002/ajh.23731
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138797
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse